Sizheng Steven Zhao1, Kazuki Yoshida2, Gareth T Jones3, David M Hughes4, Sara K Tedeschi5, Houchen Lyu6, Robert J Moots7, Daniel H Solomon8, Nicola J Goodson7. 1. University of Liverpool and Aintree University Hospital, Liverpool, UK, and Brigham and Women's Hospital, Boston, Massachusetts. 2. Brigham and Women's Hospital and Harvard T. H. Chan School of Public Health, Boston, Massachusetts. 3. University of Aberdeen, Aberdeen, UK. 4. University of Liverpool, Liverpool, UK. 5. Brigham and Women's Hospital, Boston, Massachusetts. 6. Harvard Medical School, Boston, Massachusetts, and General Hospital of Chinese PLA, Beijing, China. 7. University of Liverpool and Aintree University Hospital, Liverpool, UK. 8. Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
Abstract
OBJECTIVE: Observational data facilitate examination of treatment-effect heterogeneity, but the risk of bias is substantial. The present study was undertaken to highlight methodologic considerations through an analysis of whether smoking affects response to tumor necrosis factor inhibitors (TNFi) in axial spondyloarthritis (SpA). METHODS: We used longitudinal data from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis. Participants fulfilling the Assessment of SpondyloArthritis international Society criteria for axial SpA who started their first TNFi were eligible for analysis. In comparing the impact of smoking status, weighted generalized estimating equations were used to examine changes in several continuous outcome measures, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS). Inverse probability weights were used to account for differences in baseline covariates and excluded participants. We separately assessed response in the first 3 months to account for nonrandom dropout. RESULTS: For 840 participants who started on TNFi, 1,641 assessments from 627 individuals were analyzed (69% male, mean age 46 years). A total of 33% were current smokers and 30% ex-smokers. Ex-smokers and current smokers had worse disease than never smokers at baseline. Accounting for these differences, response did not differ according to smoking status. Compared to never smokers, ex-smokers (β = -0.6, 95% confidence interval [95% CI] -1.4, 0.3) and current smokers (β = -0.4, 95% CI -1.1, 0.4) had a similar response according to the BASDAI and ASDAS (ex-smokers β = -0.1, 95% CI -0.5, 0.3; current smokers β = -0.01, 95% CI -0.4, 0.4) at 3 months. CONCLUSION: TNFi response did not differ according to baseline smoking status in this UK cohort. Conflicting results from previous studies were likely due to methodologic differences. This analysis highlights potential sources of bias that should be addressed in future studies.
OBJECTIVE: Observational data facilitate examination of treatment-effect heterogeneity, but the risk of bias is substantial. The present study was undertaken to highlight methodologic considerations through an analysis of whether smoking affects response to tumor necrosis factor inhibitors (TNFi) in axial spondyloarthritis (SpA). METHODS: We used longitudinal data from the British Society for Rheumatology Biologics Register for Ankylosing Spondylitis. Participants fulfilling the Assessment of SpondyloArthritis international Society criteria for axial SpA who started their first TNFi were eligible for analysis. In comparing the impact of smoking status, weighted generalized estimating equations were used to examine changes in several continuous outcome measures, including the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) and the Ankylosing Spondylitis Disease Activity Score (ASDAS). Inverse probability weights were used to account for differences in baseline covariates and excluded participants. We separately assessed response in the first 3 months to account for nonrandom dropout. RESULTS: For 840 participants who started on TNFi, 1,641 assessments from 627 individuals were analyzed (69% male, mean age 46 years). A total of 33% were current smokers and 30% ex-smokers. Ex-smokers and current smokers had worse disease than never smokers at baseline. Accounting for these differences, response did not differ according to smoking status. Compared to never smokers, ex-smokers (β = -0.6, 95% confidence interval [95% CI] -1.4, 0.3) and current smokers (β = -0.4, 95% CI -1.1, 0.4) had a similar response according to the BASDAI and ASDAS (ex-smokers β = -0.1, 95% CI -0.5, 0.3; current smokers β = -0.01, 95% CI -0.4, 0.4) at 3 months. CONCLUSION: TNFi response did not differ according to baseline smoking status in this UK cohort. Conflicting results from previous studies were likely due to methodologic differences. This analysis highlights potential sources of bias that should be addressed in future studies.
Authors: M Alan Brookhart; Sebastian Schneeweiss; Kenneth J Rothman; Robert J Glynn; Jerry Avorn; Til Stürmer Journal: Am J Epidemiol Date: 2006-04-19 Impact factor: 4.897
Authors: D H Solomon; N J Goodson; J N Katz; M E Weinblatt; J Avorn; S Setoguchi; C Canning; S Schneeweiss Journal: Ann Rheum Dis Date: 2006-06-22 Impact factor: 19.103
Authors: Denis Poddubnyy; Hildrun Haibel; Joachim Listing; Elisabeth Märker-Hermann; Henning Zeidler; Jürgen Braun; Joachim Sieper; Martin Rudwaleit Journal: Arthritis Rheum Date: 2012-05
Authors: Chenglong Han; Don W Robinson; Monica V Hackett; L Clark Paramore; Kathy H Fraeman; Mohan V Bala Journal: J Rheumatol Date: 2006-09-01 Impact factor: 4.666
Authors: Paul A C Lord; Tracey M Farragher; Mark Lunt; Kath D Watson; Deborah P M Symmons; Kimme L Hyrich Journal: Rheumatology (Oxford) Date: 2009-12-23 Impact factor: 7.580
Authors: Gary J Macfarlane; Maxwell S Barnish; Elizabeth A Jones; Lesley Kay; Andrew Keat; Karen T Meldrum; Ejaz Pathan; Roger D Sturrock; Claudia Zabke; Paul McNamee; Gareth T Jones Journal: BMC Musculoskelet Disord Date: 2015-11-11 Impact factor: 2.362
Authors: Liz Van Rossen; Antoni Chan; Annie Gilbert; Karl Gaffney; Claire Harris; Pedro M Machado; Liliana R Santos; Raj Sengupta; Paul Basset; Andrew Keat Journal: Rheumatol Adv Pract Date: 2020-05-13
Authors: Sizheng Steven Zhao; Kazuki Yoshida; Gareth T Jones; David M Hughes; Stephen J Duffield; Sara K Tedeschi; Houchen Lyu; Robert J Moots; Daniel H Solomon; Nicola J Goodson Journal: Arthritis Res Ther Date: 2019-07-22 Impact factor: 5.156
Authors: Steven L Truong; Tim McEwan; Paul Bird; Irwin Lim; Nivene F Saad; Lionel Schachna; Andrew L Taylor; Philip C Robinson Journal: Rheumatol Ther Date: 2021-12-28